This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Strength Seen in PACS Group, Inc. (PACS): Can Its 21.8% Jump Turn into More Strength?
by Zacks Equity Research
PACS Group, Inc. (PACS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sotera Health (SHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of 16.67% and 3.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Tops Q1 Earnings Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 50% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Sotera Health (SHC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Sotera Health (SHC) stock based on the movements in the options market lately.
Strength Seen in Elevance Health (ELV): Can Its 3.1% Jump Turn into More Strength?
by Zacks Equity Research
Elevance Health (ELV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Compared to Estimates, Sotera Health (SHC) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of 0% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Sotera Health (SHC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 44.44% and 2.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health (SHC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Sotera Health (SHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sotera Health Company (SHC) Q3 Earnings Lag Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of -10.53% and 2.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Sotera Health Company (SHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sotera Health (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx, Inc. (CDNA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
CareDx (CDNA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Compared to Estimates, Sotera Health (SHC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of 11.76% and 3.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs (ESTA) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sotera Health Company (SHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Sotera Health (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sotera Health Company (SHC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Sotera Health Company (SHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sotera Health Company (SHC) Meets Q4 Earnings Estimates
by Zacks Equity Research
Sotera Health Company (SHC) delivered earnings and revenue surprises of 0% and 3.23%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Unveiling Sotera Health Company (SHC) Q4 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Sotera Health Company (SHC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Teladoc (TDOC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Teladoc (TDOC) delivered earnings and revenue surprises of 22.73% and 1.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sotera Health Company (SHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Sotera Health Company (SHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.